Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction

Diseases of the Esophagus

Volumn 26, Issue 3, 2013, Pages 299-304

  Phillips, B E ^a   Tubbs, R R ^c   Rice, T W ^e   Rybicki, L A ^f   Plesec, T ^d   Rodriguez, C P ^a   Videtic, G M ^b   Saxton, J P ^b   Ives, D I ^a   Adelstein, D J ^a  

^a Solid Tumor Oncology   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c Department of Molecular Pathology ^*  (United States)

^d Pathology and Laboratory Medicine Institute   (United States)

^e Heart and Vascular Institute   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Esophageal cancer; Gastric cancer; Gastroesophageal junction cancer; HER2; Trastuzumab

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISTANT METASTASIS; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84875810497     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2012.01369.x     Document Type: Article

References (26)

1. Bang Y, Chung H, Xu J etal. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27: 15S-4556.
2. Bang Y, Van Cutsem E, Feyereislova A etal. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
3. Adelstein D, Rice T, Rybicki L etal. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction. Am J Clin Oncol 2007; 30: 172-80.
4. Rodriquez C, Adelstein D, Rice T etal. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010; 5: 229-35.
5. Hoffmann M, Stoss O, Shi D etal. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.
6. Jemal A, Siegal R, Xu J etal. Cancer statistics 2010. CA Cancer J Clin 2010; 60: 277-300.
7. Edge S, Byrd D, Compton C etal. (eds.). AJCC Cancer Staging Handbook, 7th edn. New York: Springer-Verlag, 2010; 129-44.
8. Ekman S, Bergqvist M, Heldin C etal. Activation of growth factor receptors in esophageal cancer-implications for therapy. Oncologist 2007; 12: 1165-77.
9. al-Kasspooles M, Moore J, Orringer M etal. Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993; 54: 213-9.
10. Dahlberg P, Jacobson B, Dahal G etal. ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg 2004; 78: 1790-800.
11. Friess H, Fukuda A, Tang W etal. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 1999; 23: 1010-8.
12. Safran H, Dipetrillo T, Nedeem A etal. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004; 22: 67-77.
13. Yoshida K, Kuniyasu H, Yasui W etal. Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. Res Clin Oncol 1993; 119: 401-7.
14. Albarello L, Pecciarini L, Doglioni C etal. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53-9.
15. Yonemura Y, Ninomiya I, Yamaguchi A etal. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-8.
16. Allgayer H, Babic R, Gruetzner K etal. C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-9.
17. Grabsch H, Sivakumar S, Gray S etal. HER2 overexpression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65.
18. Lee H, Kim J, Uhm H etal. Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 1996; 53: 192-7.
19. Mizutani T, Onda M, Tokunaga A etal. Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer 1993; 72: 2083-8.
20. Motojima K, Furui J, Kohara N etal. ErbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 1994; 115: 349-54.
21. Nakajima M, Sawada H, Yamada Y etal. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-902.
22. Ohguri T, Sato Y, Koizumi W etal. An immunohistochemical study of c-erbB-2 protein in gastric carcinomas and lymph-node metastases: is the c-erbB-2 protein really a prognostic indicator? Int J Cancer 1993; 53: 75-9.
23. Pinto-de-Sousa J, David L, Almeida R etal. C-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002; 10: 247-56.
24. Tanner M, Hollmen M, Junttila T etal. Amplification of HER2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 215-24.
25. Tateishi M, Toda T, Minamsona Y etal. Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma. J Surg Oncol 1992; 49: 209-12.
26. Begnami M, Fukuda E, Fregnani J etal. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011; 29: 3030-6.